|1.||Rybak, Michael J: 41 articles (04/2015 - 05/2003)|
|2.||Sakoulas, George: 36 articles (07/2015 - 05/2003)|
|3.||Lamp, Kenneth C: 23 articles (10/2015 - 12/2006)|
|4.||Bayer, Arnold S: 20 articles (08/2015 - 01/2008)|
|5.||Rose, Warren E: 14 articles (10/2014 - 08/2007)|
|6.||Yang, Soo-Jin: 12 articles (08/2015 - 01/2008)|
|7.||Baltz, Richard H: 11 articles (10/2010 - 12/2005)|
|8.||Pogliano, Joseph: 10 articles (07/2015 - 07/2011)|
|9.||Yeaman, Michael R: 10 articles (04/2015 - 01/2008)|
|10.||Menichetti, Francesco: 9 articles (12/2015 - 04/2010)|
04/01/2012 - "Study data show that daptomycin, a highly bactericidal antibiotic is effective in enterococcal infections. "
12/01/2010 - "Additional controlled trials will be helpful in identifying the best strategies when using daptomycin to treat CSF infections."
06/01/2010 - "Daptomycin is a first-in-class cyclic lipopeptide that has proven efficacy for the treatment of Gram-positive infections. "
01/01/2010 - "At the time of the introduction of daptomycin into clinical practice in Australia and New Zealand, this agent retains full activity and holds promise as an important therapeutic agent for treating serious Gram positive infections, including strains resistant to multiple other drug classes."
10/01/2014 - "Daptomycin in the treatment of prosthetic joint infection by Enterococcus faecalis: safety and efficacy of high-dose and prolonged therapy."
02/01/2012 - "Our experience suggests that high-dose daptomycin may be a safe therapeutic option in staphylococcal CIED endocarditis and may be associated with high microbiological responses and clinical success."
07/01/2009 - "Daptomycin shows a good therapeutic efficacy in staphylococcal endocarditis: MRSA 71%, MSSA 75%. "
11/01/2008 - "Daptomycin has great promise in this regard as its rapid bactericidal activity makes it particularly suitable for the treatment of bacteraemia and endocarditis."
02/01/2012 - "Daptomycin at the dose of 6 mg/kg/day has been found to be effective in staphylococcal endocarditis, but limited data exist on CIED endocarditis. "
10/01/2010 - "Daptomycin is also effective in treating endocarditis with septic pulmonary infarcts."
12/01/2013 - "Time to clearance of bacteremia, 6-month mortality, and adverse events (AEs) ascribable to daptomycin were also assessed. "
01/01/2005 - "The patient's MRSA bacteremia was cleared with daptomycin therapy (6 mg/kg/d). "
11/01/2015 - "The present study was undertaken to investigate this issue using a genetically characterized series of four isogenic clinical MRSA strains derived from a patient with bacteremia before and during daptomycin treatment. "
07/01/2009 - "Our experience suggests that daptomycin may be an acceptable option for VRE bacteremia; however, larger studies should be performed before this antimicrobial is routinely used for this indication."
10/01/2007 - "Data in the current study provide insight into the clinical experience using daptomycin to treat bacteremia caused by other gram-positive pathogens. "
07/01/2013 - "This analysis suggests that daptomycin is an effective and well-tolerated treatment option for osteomyelitis and highlights the importance of optimal surgical intervention and appropriate microbiological diagnosis for clinical outcomes."
09/01/2015 - "While adult studies suggest intravenous (IV) daptomycin may by beneficial for the treatment of MRSA osteomyelitis, it is not Food and Drug Administration approved for use in pediatrics, and minimal data are available related to its use in this population. "
09/01/2015 - "While daptomycin was effective in this patient, additional research is needed to determine the true safety and efficacy of this drug for treatment of osteomyelitis caused by MRSA in pediatric patients. "
01/01/2012 - "Daptomycin appears to be an effective therapeutic choice with an acceptable safety profile in the management of osteomyelitis that does not involve hardware."
08/01/2009 - "Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry."
|5.||Soft Tissue Infections
08/01/2010 - "Daptomycin is a novel antibiotic with activity against many Gram-positive organisms that has demonstrated efficacy in the management of skin and soft tissue infections (SSTIs). "
10/01/2013 - "Safety and efficacy of daptomycin as first-line treatment for complicated skin and soft tissue infections in elderly patients: an open-label, multicentre, randomized phase IIIb trial."
09/01/2015 - "Correlation between pharmacokinetic/pharmacodynamic indices and clinical outcomes in Japanese patients with skin and soft tissue infections treated with daptomycin: analysis of a phase III study."
06/01/2013 - "This study investigates the efficacy and safety of daptomycin in Japanese patients with skin and soft tissue infections (SSTIs) caused by methicillin-resistant Staphylococcus aureus (MRSA) for regulatory filing in Japan. "
04/01/2013 - "Effectiveness and safety of daptomycin in complicated skin and soft-tissue infections and bacteraemia in clinical practice: results of a large non-interventional study."
|6.||Anti-Bacterial Agents (Antibiotics)
|3.||Prostheses and Implants (Prosthesis)
|5.||Complementary Therapies (Alternative Medicine)